Cellectis (CLLS) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. PNFP
10. NDAQ

Go back to Cellectis (CLLS) Misses Q2 EPS by 5c

Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results

November 16, 2015 5:00 PM EST

NEW YORK--(BUSINESS WIRE)--

Regulatory News:

Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced its results for the three- and nine-month periods ended September 30, 2015.

Recent Corporate Highlights

Cellectis

- Completed a series of three production runs of UCART19, its lead TALEN® gene edited product candidate, confirming the implementation of Cellectis manufacturing process in GMP conditions.

- Announced that Great Ormond Street Hospital (GOSH)... More